Comparing the current results to its competitors, Enovis reported Revenue increase in the 1 quarter 2026 by 5.42 % year on year. The revenue growth was below Enovis's competitors' average revenue growth of 8.77 %, achieved in the same quarter.
Enovis Corp, slower than the average decrease reported by the company's competitors of -39.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -39.77 %
Enovis's Comment on Competition and Industry Peers
The Prevention & Recovery segment operates in highly competitive and fragmented markets primarily in the U.S. and Europe, with key competitors including Össur and Breg, Inc. The Reconstructive segment also competes in similarly competitive and fragmented markets in the U.S. and Europe, facing competition from large companies with greater resources as well as numerous smaller niche firms. Key competitors in the Reconstructive segment include Stryker, Zimmer Biomet, and DePuy Synthes, the medical device business within Johnson & Johnson. Competition across both segments is based on factors such as innovation, product quality, product reliability, brand recognition, and price.
February 26, 2025
By In a significant leadership transition, Enovis Corporation, a prominent player in medical technology, announced on February 26, 2025, that CEO Matt Trerotola will retire once a successor is appointed. This decision comes as the company grapples with a challenging market environment, where its stock has underperformed against broader market trends.Trerotola has informed the Board of Directors of his intention to step down, initiating a succession process that reflects the company s commitment to aligning its leadership with its strategic vision. The Board is currently collaborating with an executive search firm to identify a new CEO with a growth-oriented mindset, particularly someone who embodies a stron...
September 5, 2024
Enovis Unveils Groundbreaking Foot and Ankle Solutions at AOFAS Annual Meeting Stepping boldly into the future of orthopedic surgery, Enovis Foot and Ankle is set to revolutionize the field with its latest offerings. At the upcoming AOFAS Annual Meeting, the company will introduce the highly anticipated Tarsoplasty solution and present live demonstrations of its Better Step patient-focused platform, signaling a transformative leap in foot and ankle care.The Tarsoplasty solution promises to be a game-changer in surgical procedures, leveraging state-of-the-art technology designed to optimize outcomes and enhance patient recovery. This innovative approach is expected to address a range of complex conditions wit...
August 20, 2024
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR Cones to EMPOWR Revision Knee, Witnesses Revenue SurgeIn a revolutionary stride towards optimizing revision knee surgery, Enovis Corp announced the successful completion of the first surgeries using the newly-integrated EMPOWR Cones with the EMPOWR Revision Knee system. This advancement, executed by distinguished design consultants Dr. Beau Kildow and Dr. Leonard T. Buller, marks a significant enhancement in the comprehensive portfolio dedicated to efficient revision procedures.The innovative step effectively broadens the capabilities of the EMPOWR Revision Knee system, enabling surgeons to address complex cases with increased pr...
August 19, 2024
Leading the Charge in Orthopedic Innovation: Enovis Unveils Game-Changing Ankle and Knee TechnologiesIn an era where advancements in medical technology are surging, Enovis, a prominent player in the orthopedic industry, has made significant strides with the introduction of two groundbreaking products: the STAR Ankle system and the DonJoy ROAM OA Knee Brace. Both innovations reflect the company s commitment to enhancing patient care by integrating advanced materials and user-friendly designs aimed at improving mobility and quality of life for individuals suffering from joint issues. STAR Ankle: A Revolution in Total Ankle ReplacementThe Scandinavian Total Ankle Replacement (STAR Ankle) system has long been h...
Procept Biorobotics Corporation follows a business model focused on developing medical robotics solutions for urology procedures. Their flagship product, the AquaBeam System, utilizes waterjet technology to perform minimally invasive surgeries for patients with benign prostatic hyperplasia. The company aims to improve patient outcomes and reduce healthcare costs by providing an innovative and efficient alternative to traditional surgical methods.
Orthofix Medical Inc is a company that focuses on developing and selling medical devices and orthopedic solutions to healthcare providers and patients.
Nuwellis Inc.'s business model revolves around developing and commercializing innovative therapeutic solutions, predominantly focusing on fluid management to improve outcomes for patients with critical illnesses. They aim to provide advanced medical devices and solutions to healthcare professionals, addressing the pressing need for better fluid management in critical care settings.
Monogram Orthopaedics Inc. operates on a specialized business model focused on developing and manufacturing innovative orthopedic medical devices. With a strong emphasis on research and development, they design cutting-edge solutions to address various musculoskeletal conditions. The company collaborates with healthcare professionals to test and refine their products, ensuring their efficacy and safety for patients.
Sources:
Enovis Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Enovis Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
